Nasus Pharma is developing a number of intranasal powder products aimed at assisting patients in several acute emergency situations (such as opioid overdose and anaphylactic shock) based on its microsphere technology.
Nasus's portfolio comprises a number of programs including intranasal naloxone, intranasal epinephrine, and a number of preclinical proof-of-concept programs.
Cumulative Funding Raised Over Time ($)
Employees Over Time
Nasus Pharma Climate Tech relevance
null
Latest News
No Data, yet.
Sorry, no content found under this section.
Jun 1, 2026
finance.yahoo.com
Nasus Pharma to Host Virtual KOL Event on June 10, 2026 to Discuss NS002 for the Treatment of Anaphylaxis
null
May 22, 2026
finance.yahoo.com
NSRX: Initiating Coverage – Sniffing Out a Better Solution
null
May 1, 2026
finance.yahoo.com
Nasus Pharma to Participate in Upcoming Investor Conferences
null
Apr 21, 2026
finance.yahoo.com
RedChip's Biotech Virtual Investor Conference Replays Now Available
null
Apr 7, 2026
finance.yahoo.com
RedChip's April 16 Virtual Investor Conference to Feature Companies Advancing Clinical Pipelines and Scalable Healthcare Platforms